PHAXIAM Therapeutics: Promising results from the PhagoDAIR pilot study

PHAXIAM Therapeutics has revealed the results of its PhagoDAIR pilot study, focusing on infections associated with osteoarticular prostheses. Of the 29 patients initially randomized, the “Phages” arm showed an infection control rate of 74%, confirming the safety of their anti-Staphylococcus aureus phages. The study found similar results to compassionate care treatments. Notably, relapses were less evident after salvage therapies.

PHAXIAM is now moving towards the Phase II GLORIA study planned for 2025. This next step will involve 100 patients across Europe and the United States. The objective is to consolidate the proof of concept for the clinical use of anti-S. aureus phages.